India - a biotech growth catalyst
India is among the top 12 destinations for biotechnology in the world, with approximately 3% share if the global biotechnology industry. The sector is a key contributor to India’s vision of reaching a $ 5 Trillion economy by 2024.
The sector plays a key role in the global vaccine market, as the leader in the global supply of DPT, BCG, and measles vaccines, and is also a key contributor of 70% of WHO’s vaccines (essential Immunization Schedule). India also ranks 48th on the Global Innovation Index.
The Indian biotech industry comprises of over 5,000 companies (760 core companies and 4,240 start-ups) and is aligned around five major segments: BioPharma, BioAgriculture, BioIndustrial, and combined segment of BioServices comprising of BioIT, CROs, and Research Services.
- Sector size expected to reach $150 bn from $70.2 Bn in 2020
- 12.3% year on year growth (FY20 to FY19)
- Over 4237+ biotech startups, expected to reach 10,000 by 2025.
- 760+ core biotech companies, 200+ Biotech products
- Rising contribution to national GDP (2.7% in 2020 against 2.2% in 2019)
- India led the world into Biosimilar Innovation and became the 1st country to approve and market a biosimilar in 2000 with over 98 biosimilars approved (till September 2019), which is the highest in the world
100% FDI is allowed under the automatic route for greenfield pharma.
100% FDI is allowed under the government route for brownfield pharma in upto 74% FDI is under automatic route and beyond 74% is under the government approval route.
FDI up to 100% is allowed under the automatic route for the manufacturing of medical devices.
For further details, please refer FDI Policy
Biotechnology Science Clusters
Expected CAGR (2022-2025)
World's largest producer of recombinant Hepatitis B vaccine
World's largest producer of BT Cotton with 35.7 million bales produced in FY19-20
World's highest number of USFDA approved plants outside the US.
- Industry Scenario
- FOREIGN INVESTMENT
- INDUSTRY TRENDS
- POLICIES & SCHEMES
The Indian Biotechnology industry that was valued at $70 bn in 2020 will reach $150 bn target by 2025.
The sector is divided into five major segments: BioPharma, BioAgriculture, BioIndustrial, and the combined segment of BioServices comprising of BioIT, CROs, and Research Services.
The percentage share of the biotechnology segments is:
- Bio-Pharmaceuticals: 62%
- CRO/BioIT/Research: 15%
- Bio-agriculture: 16%
- Bio-Industrial: 7%
India is also one of the first countries to have a department dedicated to Biotechnology. Moreover, the Department has also set up BIRAC (Biotechnology Industry Research Assistance Council) which is a not-for-profit agency to strengthen and empower emerging Biotechnology enterprises to undertake strategic research and innovation, by handholding them from ideation to the commercialization of their products/ technologies.
India to become the world’s most populous country by 2027
Rising public health expenditure
Government expenditure on healthcare up to 1.6% in FY20 from 1.3% in FY16, with a target of 2.5% of the country's GDP by 2025
Capacity building initiatives
Bolstered by the ‘National Biopharma Mission’, an Industry-Academia mission to skill the workforce
National Biomedical Resource Indigenisation Consortium
Enabling India to become a net exporter of affordable diagnostics and testing kits, personal protection equipment (PPE) kits and vaccines through policy, funding and removal of infrastructure and regulatory bottlenecks.
Government acting as an enabler to improve EoDB
Critical Policy initiatives such as 'Make in India’, ‘Startup India’ and ‘Atmanirbhar Bharat Abhiyan’ (boosting domestic manufacturing capacity).
Industrial Land Bank Portal
GIS - based map displaying available infrastructure for setting up business operations in the state.
Frequently VIEW ALL
Invest India closely works with
Invest India Timeline
Disclaimer: All views and opinions that may be expressed in the posts on this page as well as post emanating from this page are solely of the individual in his/her personal capacity